Definitive Healthcare (NASDAQ:DH) Downgraded by Wall Street Zen to Hold

Key Points

• Wall Street Zen downgraded Definitive Healthcare from “buy” to “hold,” while the broader analyst consensus is “Reduce,” with an average price target of $1.47.
• The stock opened at $1.05, up 1%, but remains near its 52-week low of $0.61 and well below its 52-week high of $4.35. Morgan Stanley also lowered its price target from $2.50 to $1.50.
• Definitive Healthcare slightly beat quarterly earnings expectations with $0.05 in EPS versus $0.04 forecast, though revenue of $55.20 million fell short of the $55.47 million consensus estimate.

Definitive Healthcare (NASDAQ:DH - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other brokerages have also issued reports on DH. Bank of America reissued an "underperform" rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Definitive Healthcare in a research note on Monday. Morgan Stanley cut their price objective on shares of Definitive Healthcare from $2.50 to $1.50 and set an "equal weight" rating on the stock in a report on Tuesday, August 11th. BTIG Research reissued a "neutral" rating on shares of Definitive Healthcare in a research report on Friday. Finally, Robert W. Baird set a $1.10 target price on shares of Definitive Healthcare in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Definitive Healthcare presently has an average rating of "Reduce" and a consensus target price of $1.47.

Definitive Healthcare Stock Up 1.0%

Shares of NASDAQ DH opened at $1.05 on Friday. Definitive Healthcare has a 1 year low of $0.61 and a 1 year high of $4.35. The firm's 50 day moving average price is $0.76 and its 200 day moving average price is $0.94. The firm has a market cap of $112.09 million, a P/E ratio of -0.66, a price-to-earnings-growth ratio of 12.83 and a beta of 1.40. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The company had revenue of $55.20 million during the quarter, compared to the consensus estimate of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. As a group, sell-side analysts anticipate that Definitive Healthcare will post 0.06 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Definitive Healthcare in the second quarter valued at approximately $32,000. Schonfeld Strategic Advisors LLC acquired a new position in Definitive Healthcare during the fourth quarter valued at approximately $35,000. HRT Financial LP purchased a new stake in Definitive Healthcare during the fourth quarter worth approximately $47,000. ExodusPoint Capital Management LP purchased a new stake in Definitive Healthcare during the fourth quarter worth approximately $47,000. Finally, M&T Bank Corp acquired a new stake in shares of Definitive Healthcare in the fourth quarter worth $49,000. Institutional investors and hedge funds own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source